Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.69 [0.52, 0.91] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | crucial | - |
deaths (OS) (extension) | 0.68 [0.53, 0.87] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
PFS (extension) | 0.61 [0.50, 0.75] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.58 [0.47, 0.72] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 3.63 [2.34, 5.65] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
STRAE (any grade) | 0.63 [0.39, 1.03] | | < 1 | | 0% | 1 study (1/-) | 96.8 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.16 [0.78, 1.72] | | < 1 | | 0% | 1 study (1/-) | 23.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.82 [0.53, 1.28] | | < 1 | | 0% | 1 study (1/-) | 81.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 1.23 [0.69, 2.18] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.46 [0.02, 13.80] | | < 1 | | 0% | 1 study (1/-) | 67.0 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.23 [0.01, 5.12] | | < 1 | | 0% | 1 study (1/-) | 82.1 % | NA | not evaluable | | non important | - |
Chills TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 0.34 [0.14, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.1 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Cough TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 1.85 [0.06, 55.43] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.39 [0.10, 1.52] | | < 1 | | 0% | 1 study (1/-) | 91.2 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.92 [0.06, 14.85] | | < 1 | | 0% | 1 study (1/-) | 52.2 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.92 [0.18, 4.62] | | < 1 | | 0% | 1 study (1/-) | 53.9 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 4.69 [0.54, 40.40] | | < 1 | | 0% | 1 study (1/-) | 8.1 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.46 [0.02, 13.80] | | < 1 | | 0% | 1 study (1/-) | 67.0 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.46 [0.04, 5.11] | | < 1 | | 0% | 1 study (1/-) | 73.5 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 0.46 [0.04, 5.11] | | < 1 | | 0% | 1 study (1/-) | 73.5 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.46 [0.04, 5.11] | | < 1 | | 0% | 1 study (1/-) | 73.5 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.92 [0.06, 14.85] | | < 1 | | 0% | 1 study (1/-) | 52.2 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.46 [0.02, 13.80] | | < 1 | | 0% | 1 study (1/-) | 67.0 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 0.46 [0.02, 13.80] | | < 1 | | 0% | 1 study (1/-) | 67.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.46 [0.02, 13.80] | | < 1 | | 0% | 1 study (1/-) | 67.0 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.92 [0.06, 14.85] | | < 1 | | 0% | 1 study (1/-) | 52.2 % | NA | not evaluable | | non important | - |
Pruritic rash TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.92 [0.02, 46.74] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.46 [0.02, 13.80] | | < 1 | | 0% | 1 study (1/-) | 67.0 % | NA | not evaluable | | non important | - |